Skip to content

Low-Intensity versus Medium-Intensity continuous kidney replacement Therapy for critically ill patients

Low-Intensity versus Medium-Intensity continuous kidney replacement Therapy for critically ill patients (LIMIT): A multicentre randomised clinical trial - LIMIT trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031230292
Enrollment
400
Registered
2023-08-15
Start date
2023-11-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe acute kidney injury requiring continuous kidney replacement therapy Acute kidney injury

Interventions

Enrolled patients will be randomly allocated to the Low-intensity group or the Medium-intensity group. In the Low-intensity group, a total of 12 mL/kg/hr of replacement and/or dialysis fluid will be a
D000079664, D017582
continuous kidney replacement Therapy

Sponsors

Fujii Tomoko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The following inclusion criteria must be met by all participants, and consent must be obtained. 1. Adults (18 years or older) admitted to the intensive care unit* *High care units are also included if continuous monitoring is conducted, and an intensivist is responsible for the medical care 2.Diagnosed with acute kidney injury based on the KDIGO criteria (meeting any of the following) - Serum creatinine has increased by 0.3mg/dL or more within 48 hours - Serum creatinine has increased 1.5 times or more from the baseline, and the increase has occurred within 7 days - Oliguria (<0.5mL/kg/hr) persists for 6 hours or more 3.Treating physician adjudicates that continuous kidney replacement therapy is necessary

Exclusion criteria

Exclusion criteria: Participants will be excluded if they meet any of the following exclusion criteria: 1. Receiving chronic dialysis or planning to initiate chronic dialysis. 2. Having received any form of kidney replacement therapy or blood purification therapy within 48 hours. 3. Kidney replacement therapy using other dialysis fluids or replacement fluids, such as citrate dialysis, is preferred. 4. Other blood purification techniques, such as plasmapheresis, are combined. 5. Imminent death. 6. Previous participation in the study. 7. No consent to participate. 8. A patient who is deemed inappropriate for participation in this study by the investigator.

Design outcomes

Primary

MeasureTime frame
Composite of death and duration of kidney replacement therapy at 28 days (28-day KRT-free days)

Secondary

MeasureTime frame
1. ICU death within 90 days 2. Hospital death within 90 days 3. Dialysis dependence at hospital discharge within 90 days 4. 28-day vasopressor-free days 5. 28-day ventilator-free days 6. Serum creatinine level at the end of kidney replacement therapy (on the final day and the day before) 7. 24-hour urine output at the end of kidney replacement therapy (on the final day and the day before)

Contacts

Public ContactTomoko Fujii

The Jikei University Hospital

tomoko1109@gmail.com+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026